

1/7/21

Freedom of Information request 015744

I am analysing the treatment of lung cancer and would greatly appreciate if you could answer the following questions:

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- Atezolizumab monotherapy - 3
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel - 1
- Bevacizumab - 6
- Docetaxel monotherapy - 13
- Durvalumab - 2
- Gemcitabine - 17
- Nivolumab - 4
- Paclitaxel - 31
- Pembrolizumab monotherapy - 14
- Pembrolizumab chemo in combination - 9
- Pemetrexed with Carboplatin - 11
- Pemetrexed with Cisplatin - 0
- Vinorelbine and cisplatin/carboplatin - 0
- Afatinib - 2
- Alectinib - 2
- Brigatinib - 0
- Ceritinib - 0
- Crizotinib - 0
- Dacomitinib - 1
- Dabrafenib with Trametinib - 0
- Erlotinib - 0
- Gefitinib - 1
- Nintedanib with Docetaxel - 1
- Osimertinib - 4

Q2. Could you please provide the total number of patients treated with any systemic anti-cancer therapy (SACT) in the last three months for:

- Total non-small cell lung cancer (NSCLC) - 20 patients
- Squamous non-small cell lung cancer (Sq NSCLC) - 4 patients
- Non-squamous non-small cell lung cancer (Non-Sq NSCLC) - 14 patients

Q3. Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part? - Not currently